TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000431167
  • Gene Name:PRC2
  • mRNA database:Ensembl
  • mRNA expression :down-regulated
  • mRNA Method:qRT-PCR
  • mRNA Pathway:NA
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:NA
  • Drug Name:3-deazaneplanocin A
  • Drug Method:down-regulated the gene expression the gene expression

Disease basic infommation

  • Disease:biliary tract cancer
  • Tissue:cell lines (CCSW-1, BDC, EGI-1, SkChA-1, TFK-1,MzChA-1, MzChA-2 ,GBC)

Other information

  • Title:3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer
  • Journal:Anticancer Res
  • Published:2015
  • PubMed ID:26254359
  • Abstract:Background/aim:Polycomb repressive complex 2 (PRC2), an epigenetic master regulator, contributes to progression and development of biliary tract cancer (BTC). The present study investigated the effects of the PRC2 inhibitor 3-deazaneplanocin A (DZNep) on BTC cell lines. Materials and methods:In vitro effects of DZNep treatment were analyzed for cell viability, gene expression and functional characteristics of cancer stem cell (CSC). Results:DZNep treatment caused a cell line- and dose-dependent decrease in viability. In the EGI-1 cell line, a direct cytotoxic effect was accompanied by mRNA down-regulation of the PRC2 core components, cyclins as well as of CSC-related genes. Furthermore, DZNep affected putative CSCs by reduction of sphere formation and aldehyde dehydrogenase-1-positive cells. The stem cell characteristics of these subpopulations were verified by real-time polymerase chain reaction analysis. Conclusion:Taken together, our results show that DZNep might be a promising pharmacological agent for future therapies regarding BTC. Keywords: Biliary tract cancer; DZNep; EZH2; PRC2; anchorage-independent growth; cancer stem cells.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3